L. Fonctionnement-de and . Pgp, hydrolyse de l'ATP, multiplicité de reconnaissance, p.29

O. Mise-en, Détection des cas probables, p.66

.. Saisie-du-premier-filtre, Effet indésirable central", p.67

". Etape-optionnelle, Saisie du second filtre "Inhibiteur, p.68

I. Principaux-effets, Effets indésirables liés à l'inhibition de la P-gp, p.80

P. Girard, Membranes hors d'équilibre: échanges et transport actif

M. Mourez, M. Jéhanno, M. Hofnung, and E. Dassa, Rôle, fonctionnement et structure des transporteurs à ATP binding cassette (ABC). 2000 [Dernière consultation le 12 août 2016]; Disponible sur, 1658.
DOI : 10.4267/10608/1658

P. Jones and A. George, The ABC transporter structure and mechanism: perspectives on recent research, Cellular and Molecular Life Sciences (CMLS), vol.61, issue.6, pp.682-99, 2004.
DOI : 10.1007/s00018-003-3336-9

M. Dean and T. Annilo, EVOLUTION OF THE ATP-BINDING CASSETTE (ABC) TRANSPORTER SUPERFAMILY IN VERTEBRATES, Annual Review of Genomics and Human Genetics, vol.6, issue.1, pp.123-165, 2005.
DOI : 10.1146/annurev.genom.6.080604.162122

J. Stefková, R. Poledne, and J. Hubácek, ATP-binding cassette (ABC) transporters in human metabolism and diseases, Physiol Res Acad Sci Bohemoslov, vol.53, issue.3, pp.235-278, 2004.

G. Zaman, C. Versantvoort, J. Smit, E. Eijdems, M. De-haas et al., Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines, Cancer Res, vol.53, issue.8, pp.1747-50, 1993.

R. Juliano and V. Ling, A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants, Biochimica et Biophysica Acta (BBA) - Biomembranes, vol.455, issue.1, 1976.
DOI : 10.1016/0005-2736(76)90160-7

K. Chin, S. Tanaka, G. Darlington, I. Pastan, and M. Gottesman, P-glycoprotein) in human normal and tumor tissues Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells, MR. Expression of the multidrug resistance gene product, pp.221-227, 1990.

E. Rowinsky, The Vinca Alkaloids, Int J Prev Med, vol.4, issue.11, 2013.

A. Ward, P. Szewczyk, V. Grimard, C. Lee, L. Martinez et al., PGP Gene -GeneCards | PGP Protein | PGP Antibody 15, pp.1231-1235, 200314.

S. Ambudkar, C. Kimchi-sarfaty, Z. Sauna, and M. Gottesman, P-glycoprotein: from genomics to mechanism, Oncogene, vol.22, issue.47, pp.7468-85, 2003.
DOI : 10.1038/sj.onc.1206948

URL : http://www.nature.com/onc/journal/v22/n47/pdf/1206948a.pdf

S. Aller, Y. J. Ward, A. Weng, Y. Chittaboina, S. Zhuo et al., Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding, Science. 27 mars, vol.323, issue.5922, pp.1718-1740, 2009.

P. Yeagle, M. Borgnia, G. Eytan, and Y. Assaraf, Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity, J Biol Chem, vol.271, issue.6, pp.3163-71, 1996.

J. Ribarska, The association of C3435T single-nucleotide polymorphism, Pgpglycoprotein gene expression levels and carbamazepine maintenance dose in patients with epilepsy, 191?6. 21. Sakaeda T, 2012.

T. Sakai, MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects Pharmacokineticpharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition, 1400?4. 22. Dresser GK, pp.41-57, 2000.

M. Sababi, O. Borgå, and U. Hultkvist-bengtsson, The role of P-glycoprotein in limiting intestinal regional absorption of digoxin in rats, European Journal of Pharmaceutical Sciences, vol.14, issue.1, pp.21-28, 2001.
DOI : 10.1016/S0928-0987(01)00161-0

C. Higgins, ABC Transporters: From Microorganisms to Man, Annual Review of Cell Biology, vol.8, issue.1, pp.67-113, 1992.
DOI : 10.1146/annurev.cb.08.110192.000435

X. Declèves, J. Schermann, and S. Cisternino, Blood-brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of P-glycoprotein on a novel verapamil influx carrier: Drug efflux/influx at brain and retina barriers, Br J Pharmacol. févr, vol.173, issue.3, pp.497-510, 2016.

P. Borst and A. Schinkel, P-glycoprotein ABCB1: a major player in drug handling by mammals, Journal of Clinical Investigation, vol.123, issue.10, pp.4131-4134, 2013.
DOI : 10.1172/JCI70430

J. Ferté, Analysis of the tangled relationships between

U. Zanger, Frequency of C3435T polymorphism of MDR1 gene in African people, Lancet Lond Engl. 4 août, vol.358, issue.9279, pp.383-387, 2001.

I. Llaudó, L. Cassis, J. Torras, O. Bestard, M. Franquesa et al., Impact of Small Molecules Immunosuppressants on P-Glycoprotein Activity and T-cell Function, Journal of Pharmacy & Pharmaceutical Sciences, vol.15, issue.3, pp.407-426, 2012.
DOI : 10.18433/J3G30B

T. Ozben, Mechanisms and strategies to overcome multiple drug resistance in cancer, FEBS Letters, vol.52, issue.12, pp.2903-2912, 2006.
DOI : 10.1016/j.jss.2004.11.011

URL : http://onlinelibrary.wiley.com/doi/10.1016/j.febslet.2006.02.020/pdf

C. Muller, J. Bailly, F. Goubin, J. Laredo, J. Jaffrézou et al., Verapamil decreases P-glycoprotein expression in multidrug-resistant human leukemic cell lines, International Journal of Cancer, vol.48, issue.5, pp.749-54, 1994.
DOI : 10.1128/MCB.2.8.881

J. Lin, M. Drug-rue, E. Blood, W. Dalton, C. Shustik et al., Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group, 53?81. 35. Friedenberg WR, pp.830-838, 2003.

D. Miller, B. Bauer, and A. Hartz, ):e1143544. 37 Modulation of P-Glycoprotein at the Blood-Brain Barrier: Opportunities to Improve Central Nervous System Pharmacotherapy, Pharmacol Rev. 15 mai, vol.460, issue.12, pp.196-209, 2008.

J. Correale and A. Villa, Cellular Elements of the Blood-Brain Barrier, Neurochemical Research, vol.51, issue.12
DOI : 10.1089/ars.2007.1713

M. Mato, S. Ookawara, M. Sugamata, and E. Aikawa, Evidence for the possible function of the fluorescent granular perithelial cells in brain as scavengers of high-molecular-weight waste products, 399?402. 41. Matter K, Balda MS. Signalling to and from tight junctions, 1984.
DOI : 10.1007/BF01952574

P. Couraud, ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood?brain barrier, J Neurochem, vol.107, issue.6, pp.1518-1546, 2008.

R. Perrin, A. Minn, J. Ghersi-egea, M. Grassiot, and G. Siest, Distribution of cytochrome p450 activities towards alkoxyresorufin derivatives in rat brain regions, subcellular fractions and isolated cerebral microvessels, Biochemical Pharmacology, vol.40, issue.9, pp.2145-51, 1990.
DOI : 10.1016/0006-2952(90)90247-I

M. Krohn, Vascular and extravascular distribution of the ATP-binding cassette transporters ABCB1 and ABCC1 in aged human brain and pituitary141?142:12?21. 46. Fry M, Ferguson AV. The sensory circumventricular organs: brain targets for circulating signals controlling ingestive behavior, Mech Ageing Dev. nov Physiol Behav, vol.91, issue.4, pp.413-436, 2007.

C. Page and . Pharmacologie-intégrée, De Boeck Supérieur, 1999.

M. Seronde and . Cours, Digoxine -Digitoxine. [Dernière consulation le 12 août 2016] Disponible sur: http://www.besancon-cardio.org/cours/62-digoxine- digitoxine.php 52. Correspondence. Dtsch Aerzteblatt Online. 22 janv 2016 ; Disponible sur

M. Talbert, G. Willoquet, R. Gervais, and J. Calop, Guide pharmaco clinique

J. Aronson and L. Meyler, Meyler's side effects of drugs: the international encyclopedia of adverse drug reactions and interactions, pp.2016-57

T. Lee, S. Van-gogh-madreperla, M. Johnson, and K. Nakatani, s Vision: Digitalis Intoxication? JAMA. 20 févr Electrophysiologic and electroretinographic evidence for photoreceptor dysfunction as a toxic effect of digoxin, Arch Ophthalmol, vol.245112, issue.586, pp.727807-727819, 1981.

S. Fujii, C. Setoguchi, K. Kawazu, and K. Hosoya, Impact of P-Glycoprotein on Blood?Retinal Barrier Permeability: Comparison of Blood?Aqueous Humor and Blood?Brain Barrier Using Mdr1a Knockout Rats, Investig Opthalmology Vis Sci

M. Hammarlund-udenaes, Validation of a P-Glycoprotein (P-gp) Humanized Mouse Model by Integrating Selective Absolute Quantification of Human MDR1, Mouse Mdr1a and Mdr1b Protein Expressions with In Vivo Functional Analysis for

J. Geyer, O. Gavrilova, and E. Petzinger, The Role of P-Glycoprotein in

A. Schinkel, E. Wagenaar, C. Mol, and L. Van-deemter, P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs., Journal of Clinical Investigation, vol.97, issue.11, pp.2517-63, 1996.
DOI : 10.1172/JCI118699

R. Mccallum, Motility Agents and the Gastrointestinal Tract, The American Journal of the Medical Sciences, vol.312, issue.1
DOI : 10.1097/00000441-199607000-00004

C. Paul, M. Zenut, A. Dorut, M. Coudore, J. Vein et al., Use of Domperidone as a Galactagogue Drug, Journal of Human Lactation, vol.156, issue.3, pp.57-63, 2015.
DOI : 10.1016/j.toxlet.2004.12.008

B. Osante and C. Aguirre, Domperidone in Parkinson's disease: a perilous arrhythmogenic or the gold standard?, Curr Drug Saf. févr, vol.8, issue.1, pp.63-71, 2013.

I. Soykan, I. Sarosiek, J. Shifflett, G. Wooten, and R. Mccallum, Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with parkinson's disease, ):952?7. 67. Zuppa AA, 1997.
DOI : 10.1212/WNL.38.3.419

J. Barone, -Receptor Antagonist, Annals of Pharmacotherapy, vol.108, issue.5, pp.429-469, 1999.
DOI : 10.3109/00365529409094839

URL : https://hal.archives-ouvertes.fr/hal-01480811

J. Heykants, A. Knaeps, W. Meuldermans, and M. Michiels, On the pharmacokinetics of domperidone in animals and man I. Plasma levels of domperidone in rats and dogs. Age related absorption and passage through the blood brain barrier in rats, European Journal of Drug Metabolism and Pharmacokinetics, vol.177, issue.Suppl. 1, pp.27-36, 1981.
DOI : 10.1007/BF03189513

M. Decressac, I. Frappé, P. Fernagut, L. Prestoz, and S. Besnard, Pharmacokinetics and Therapeutic Efficacy in the Symptomatic Treatment of Chronic Dyspepsia and as an Antiemetic Anatomical and functional reconstruction of the nigrostriatal pathway by intranigral transplants, Domperidone: A Review of its Pharmacological Activity477?88. 73. Collège des enseignants en Neurologie -Maladie de Parkinson, 1982.

D. Lyons, A. Hellysaz, C. Broberger, M. Freeman, B. Kanyicska et al., Prolactin regulates tuberoinfundibular dopamine neuron discharge pattern: novel feedback control mechanisms in the lactotrophic axis Prolactin: structure, function, and regulation of secretion, Disponible surMaladies%20et%20grands%20syndromes/Maladie%20de%20Parkinson/ind ex.phtml#IV 74, pp.1523-631, 2000.

. Médicaments-actifs-sur-le-système, Cachan: Éd Médicales internationales; 2011. 77. Swift RM, Griffiths W, Cammera P. False positive urine drug screens from quinine in tonic water, Addict Behav, vol.14, issue.2, pp.213-218, 1989.

K. Yasuda, Interaction of Cytochrome P450 3A Inhibitors with

A. Sadeque, R. Kim, C. Stein, G. Wilkinson, and D. Roden, Increased drug delivery to the brain by P-glycoprotein inhibition Inhibition of P-Glycoprotein Mediated Drug Transport : A Unifying Mechanism to Explain the Interaction Between Digoxin and Quinidine. Circulation. 2 févr, ):231?7. 80. Fromm MF552?7. 81. Revue Prescrire, Cahier Penser et prescrire en DCI octobre, 1999.